Company research
Lantern Pharma Inc.
CIK 1763950Updated Sep 26, 2026
SecurityLTRN · NASDAQ · equity
Name history
Lantern Pharma · through Jan 14, 2019
LTRN price & chart
Loading TradingView…
NASDAQ:LTRN on TradingView ↗About the company
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, re…
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
SCHEDULE 13G filing
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
EFFECT filing
S-1 filing
Regulation FD Disclosure
Items 7.01, 9.01
D filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,035,811Source | 25,571,792Source | 43,647,616Source | 58,836,321Source |
| Property, Plant and Equipment, NetUSD | 31,875Source | 47,440Source | 52,127Source | 48,008Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,422,838Source | 7,511,079Source | 21,937,749Source | 37,201,786Source |
| Assets, CurrentUSD | 10,803,172Source | 25,247,629Source | 43,341,325Source | 58,722,737Source |
| Prepaid Expense and Other Assets, CurrentUSD | 683,948Source | 1,234,566Source | 2,038,653Source | 2,985,472Source |
| Operating Lease, Right-of-Use AssetUSD | 75,595Source | 239,985Source | 228,295Source | 47,687Source |
| Other Assets, NoncurrentUSD | 36,738Source | 36,738Source | 25,869Source | 17,889Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,501,587Source | 4,384,018Source | 2,739,682Source | 2,798,297Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,125Source | 1,078Source | 1,072Source | 1,086Source |
| Additional Paid in CapitalUSD | 99,652,724Source | 97,058,323Source | 96,258,726Source | 95,691,194Source |
| Retained Earnings (Accumulated Deficit)USD | -93,145,055Source | -76,025,617Source | -55,244,404Source | -39,282,870Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 25,430Source | 153,990Source | -107,460Source | -371,386Source |
| Stockholders' Equity Attributable to ParentUSD | 6,534,224Source | 21,187,774Source | 40,907,934Source | 56,038,024Source |
| Liabilities and EquityUSD | 11,035,811Source | 25,571,792Source | 43,647,616Source | 58,836,321Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,501,587Source | 4,331,175Source | 2,678,186Source | 2,798,297Source |
| Operating Lease, Liability, CurrentUSD | 78,539Source | 190,814Source | 172,975Source | 52,890Source |
| Operating Lease, Liability, NoncurrentUSD | — | 52,843Source | 61,496Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 14,615Source | 10,081Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 651,000Source | 652,000Source | 1,067,515Source | 1,187,745Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,676,980Source | -17,813,201Source | -14,346,548Source | -12,767,492Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 11,057,073Source | 3,369,368Source | -930,210Source | 179,268Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,715Source | 12,595Source | 18,734Source | 27,844Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 499,997Source | 2,482,286Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,498,240Source | 66,710Source | -499,997Source | -2,182,498Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,088,241Source | -14,426,670Source | -15,805,217Source | -14,781,329Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 61,318Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 22,408Source | 9,065Source | -115,840Source | -128,922Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 157,965Source | -219,729Source | -11,500Source | -58,598Source |
| General and Administrative ExpenseUSD | 6,464,371Source | 6,090,747Source | 5,983,255Source | 5,829,799Source |
| Net Income (Loss) Attributable to ParentUSD | -17,119,438Source | -20,781,213Source | -15,961,534Source | -14,259,946Source |
| Operating ExpensesUSD | 17,978,494Source | 22,216,437Source | 17,877,570Source | 14,432,753Source |
| Other Nonoperating Income (Expense)USD | 421,125Source | 692,869Source | 1,150,648Source | -31,548Source |
| Proceeds from Issuance of Common StockUSD | 1,624,547Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 13,442Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 305,887Source | 155,624Source | 119,650Source | -492,501Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -17,978,494Source | -22,216,437Source | -17,877,570Source | -14,432,753Source |
| Other Nonoperating Income (Expense)USD | 421,125Source | 692,869Source | 1,150,648Source | -31,548Source |
| Net Income (Loss) Attributable to ParentUSD | -17,119,438Source | -20,781,213Source | -15,961,534Source | -14,259,946Source |
| Earnings Per Share, BasicUSD per share | -1.57Source | -1.93Source | -1.47Source | -1.31Source |
| Earnings Per Share, DilutedUSD per share | -1.57Source | -1.93Source | -1.47Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 10,898,175Source | 10,762,319Source | 10,842,365Source | 10,850,579Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 10,898,175Source | 10,762,319Source | 10,842,365Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 17,280Source | 17,282Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 157,965Source | -219,729Source | -11,500Source | -58,598Source |
| General and Administrative ExpenseUSD | 6,464,371Source | 6,090,747Source | 5,983,255Source | 5,829,799Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 16,980,000Source | — | — | — |
| Interest Income, OtherUSD | 437,931Source | 742,355Source | 765,388Source | 204,355Source |
| Operating ExpensesUSD | 17,978,494Source | 22,216,437Source | 17,877,570Source | 14,432,753Source |
| Other General and Administrative ExpenseUSD | — | — | — | 144,000Source |
| Research and Development ExpenseUSD | 11,514,123Source | 16,125,690Source | 11,894,315Source | 8,602,954Source |
Offerings
Registration 333-296752
Filing attachments
ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET Management will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussion Investors, collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform’s key cap…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned to Advance in Multiple Indications including Triple Negative Breast Cancer and P…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities. The creation of the new entity, signed commercial licenses, and Board approvals are con…
Read attachment ↗